Data Characteristics
Pharmacovigilance data for stem cell therapy originates from diverse sources. These include clinical trial reports, real-world evidence (RWE) data, spontaneous reporting systems (e.g., FAERS, EudraVigilance), and literature reviews. Data update frequencies vary. Clinical trial data typically releases at specific time points, while spontaneous reporting systems provide continuous data streams. Document structures are complex, containing unstructured free text descriptions (e.g., patient complaints, adverse event details), semi-structured tables (e.g., medication history, comorbidities), and structured coded data (e.g., MedDRA terms, WHO-DD drug codes). Specific fields and units often involve qualitative descriptions for adverse event severity and causality assessment, requiring evaluation by clinical experts. Unique fields like stem cell source, preparation process, and administration route are crucial for understanding adverse reaction mechanisms and risk assessment.
Constraints on Workflow Orchestration
The heterogeneous nature of stem cell therapy pharmacovigilance data requires robust multi-format parsing capabilities during data ingestion. The workflow must handle PDF, Word documents, CSV tables, and JSON structured data. The prevalence of unstructured text necessitates integrating advanced Natural Language Processing (NLP) modules for entity recognition (e.g., adverse events, drugs, indications), relationship extraction, and sentiment analysis to extract key information from vast amounts of text. Inconsistent update frequencies mean the workflow must support multiple trigger mechanisms, including scheduled triggers (e.g., weekly, monthly reports), event-driven triggers (e.g., new report submission), and manual triggers. The complexity of qualitative assessments demands a workflow that can flexibly integrate human review nodes or expert decision support systems, enabling human-in-the-loop collaboration. Analyzing unique stem cell fields requires higher demands on data integration and knowledge graph construction within the workflow to ensure comprehensive capture and precise traceability of risk signals.
Configuration Guidelines
| Configuration Item | Recommended Approach | Rationale |
|---|---|---|
maxContext | 4096 tokens | Accommodates longer adverse event descriptions and clinical background information in stem cell therapy reports. |
Chunk size (Chunk Length) | 500-800 characters (characters) | Balances semantic integrity with chunk processing efficiency, preventing critical information truncation. |
Recall count (Recall Count) | Top 10-15 entries (top 10-15 items) | Ensures coverage of as many potentially relevant adverse event reports as possible during initial retrieval. |
Similarity threshold (Similarity Threshold) | 0.75-0.85 | Filters out low-relevance results while retaining semantically similar stem cell therapy-related events. |
Parsing Model | text-embedding-ada-002 | Suitable for semantic understanding and vector representation of biomedical texts. |
Callback Timeout | 600 seconds (seconds) | Addresses potential delays in complex report processing, external tool calls, and expert system responses. |
Common Pitfalls
- Workflow execution times out with a
504 Gateway Timeoutstatus code. This occurs due to underestimating the time required to process unstructured text and perform complex causality assessments, leading to excessively long single-step task execution times. - Adverse event fields are empty or incomplete. This happens when data preprocessing lacks effective identification and extraction rules for non-standard fields unique to stem cell therapy (e.g., stem cell source, preparation batch).
- Risk signals are missed, and the system fails to identify new potential safety issues. This results from setting the similarity matching threshold too high, causing novel adverse reactions with slight differences from the existing knowledge base but clinical significance to not be recalled.
Validation Steps
- Select representative stem cell therapy adverse event reports. Manually simulate data input and observe if the workflow accurately parses key entities (e.g., drug, adverse event, dosage, time) from the report. Compare the output against expected results.
- Submit reports containing known risk signals. Check if the workflow accurately identifies them and triggers corresponding risk alerts or human review processes. Evaluate the timeliness and accuracy of these alerts.
- Randomly sample a batch of reports. Query the structured data output by the workflow and verify the completeness and accuracy of key fields (e.g., MedDRA coding, causality assessment). Ensure data quality meets subsequent analysis requirements.
Note: The values provided are common starting points. Measure performance against specific samples to determine optimal configurations.
Question material comes from public community discussions. Configuration values are common starting points and should be measured against your own samples. Verified on 2026-09-21.